New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2013
16:33 EDTTWTR, FB, ANIP, TEVA, TXTROn The Fly: Closing Wrap
Stocks on Wall Street were lower, but just slightly, as volume remained extremely light in the markets as it has each day during this shortened holiday trading week. ECONOMIC EVENTS: In the U.S., no major economic data was released. COMPANY NEWS: Twitter (TWTR) fell sharply, losing $9.56, or 13.04%, to $63.75 after shares of the social platform operator were downgraded at research firm Macquarie, which said the stock's recent surge is unjustified. Twitter stock, which had jumped 40% from December 11 through the close of trading yesterday, has climbed "too far, too fast," though there has been no change in Twitter's fundamentals since that date, Macquarie's analyst contended.... Shares of social network Facebook (FB) were also among the session's largest losers, falling $2.29, or 3.97%, to $55.44 as the tech-heavy Nasdaq posted the largest decline of the major equity indexes. MAJOR MOVERS: Among the notable gainers was Textron (TXT), up 41c, or 1.13%, to $36.61 after announcing an agreement to acquire fellow aircraft maker Beechcraft for $1.4B in cash, confirming reports last week from the Financial Times regarding the deal. Also advancing were shares of ANI Pharmaceuticals (ANIP), up $2.77, or 16.18%, to $19.89 after the company acquired 31 previously marketed generic drug products from Teva Pharmaceuticals (TEVA). Among the notable losers was Textura (TXTR), down $1.76, or 5.62%, to $29.54 in its second straight losing session following a Citron Research report yesterday alleging that fraud, collusion, and deception were involved in the company's IPO. Analysts at William Blair called the sell-off a buying opportunity. INDEXES: The Dow was down 1.47, or 0.01%, to 16,478.41; the S&P 500 was down 0.62, or 0.03%, to 1,841.40; the Nasdaq was down 10.59, or 0.25%, to 4,156.59.
News For TWTR;FB;ANIP;TEVA;TXTR From The Last 14 Days
Check below for free stories on TWTR;FB;ANIP;TEVA;TXTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 5, 2014
19:30 EDTTWTRTwitter to launch new ad products, WSJ says
In a push to appease e-commerce companies and mobile-game developers, Twitter is planning to debut 15 types of new ad products and ways to target users over the coming six months, says the Wall Street Journal, citing sources. The first group of new adds will be released in a few weeks and will include a product that encourages users to download apps through Twitter, added the Wall Street Journal. Reference Link
April 4, 2014
17:12 EDTFBMarket finishes mixed as Nasdaq sells off into weekend
Subscribe for More Information
16:30 EDTFBOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTTWTROptions Update; April 4, 2014
iPath S&P 500 VIX Short-Term Futures up 89c to 41.88. Option volume leaders: AAPL C P NFLX LNG BAC INTC TSLA TWTR according to Track Data.
11:31 EDTTWTRStocks with call strike movement; JCP TWTR
Subscribe for More Information
10:45 EDTTEVAMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
09:36 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
08:02 EDTFBFacebook met with anonymous app maker Secret but didn't make offer, Re/code says
Subscribe for More Information
06:12 EDTFBFacebook paid researchers $1.5M to fix software bugs
Facebook paid out more than $1.5M to security researchers who helped it find and fix software bugs and security vulnerabilities in its software code, the company said. The company says it has been working to grow its bug bounty program since 2011, and "We received 14,763 submissions in 2013, a 246% increase from 2012. Of these, 687 were valid and eligible to receive rewards. 6% of eligible bugs were categorized as high severity. We've paid over $2M since we got started in 2011, and in 2013 we paid out $1.5M to 330 researchers across the globe. 2014 is looking good so far. The volume of high-severity issues is down, and we're hearing from researchers that it's tougher to find good bugs." Reference Link
April 3, 2014
16:00 EDTTWTROptions Update; April 3, 2014
Subscribe for More Information
15:28 EDTTWTRTwitter introduces Vine message service
Subscribe for More Information
14:30 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
13:38 EDTFBFacebook retests the $60 area, levels to watch
Subscribe for More Information
12:37 EDTTWTRTwitter downside accelerates, levels to watch
Subscribe for More Information
11:55 EDTTWTRStocks with call strike movement; JCP TWTR
Subscribe for More Information
10:53 EDTTWTRTwitter ban lifted by Turkey, official says, Reuters reports
Subscribe for More Information
07:44 EDTTWTRTurkey court orders Erdogan government to remove Twitter ban, Bloomberg says
Subscribe for More Information
06:10 EDTFBGoogle's LeBeau hired by Facebook, TechCrunch reprots
Google (GOOG) product designer Mike LeBeau has been hired by Facebook (FB), TechCrunch reports. LeBeau had a hand in developing several voice-related technologies, including iPhone Voice Search, while working as a staff software engineer and product designer at Google, and was an early member of the Android team. LeBeau will become a product manager at Facebook. Reference Link
06:01 EDTFBInstagram fixing bug that hides users' photos, AP reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use